Market revenue in 2023 | USD 181.2 million |
Market revenue in 2030 | USD 364.7 million |
Growth rate | 10.5% (CAGR from 2023 to 2030) |
Largest segment | Surgery |
Fastest growing segment | Intralesional injections |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Radiotherapy (RT), Intralesional injections, Intravenous Medications, Chemical peeling treatment, Surgery, Topical chemotherapy, Oral Medications |
Key market players worldwide | Bausch Health Companies Inc, Almirall SA, Genentech, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Dr Reddy's Laboratories Ltd ADR, Taro Pharmaceuticals, Accord Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to basal cell carcinoma treatment market will help companies and investors design strategic landscapes.
Surgery was the largest segment with a revenue share of 35.87% in 2023. Horizon Databook has segmented the Canada basal cell carcinoma treatment market based on radiotherapy (rt), intralesional injections, intravenous medications, chemical peeling treatment, surgery, topical chemotherapy, oral medications covering the revenue growth of each sub-segment from 2018 to 2030.
Canada’s market is expected to grow at a lucrative rate over the forecast period. Canada has a high incidence of skin cancer, including BCC. The Canadian Skin Cancer Foundation reports that NMSCs are the most common form of cancer in Canada.
BCC affects approximately 50,000 to 60,000 Canadians each year. According to the International Agency for Research on Cancer, in 2022, the U.S. reported 56,330 prominent cases of NMSC.
The rising prevalence is likely to drive the demand for effective treatments and boost the basal cell carcinoma treatment market. Canada's population is aging, with a significant portion of the population over the age of 65 years.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada basal cell carcinoma treatment market , including forecasts for subscribers. This country databook contains high-level insights into Canada basal cell carcinoma treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account